Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGM2 | P21980 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.47 |
| ▸ | CDK9 | P50750 | 1/20 | 0.47 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 2/20 | 0.41 |
| ▸ | MAOB | P27338 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | ACP1 | P24666 | 2/20 | 0.39 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23982850 | 0.89 | TGM2 (0.53) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL23050881 | 0.87 | TGM2 (0.47) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL22446478 | 0.85 | SMN1; SMN2 (0.47) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL19993557 | 0.84 | TGM2 (0.48) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL19403907 | 0.82 | SMN1; SMN2 (0.47) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL21008326 | 0.82 | NPC1 (0.47) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL18648512 | 0.82 | TGM2 (0.41) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL20143892 | 0.80 | TGM2 (0.41) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL25452834 | 0.76 | SMN1; SMN2 (0.52) | TGM2SMN1; SMN2TP53EPHX1TSHR | |
| SCHEMBL18784903 | 0.76 | ALDH1A1 (0.44) | KMT2AMEN1MAPTTAAR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021041600-A2 | HEAT SENSITIVE RECORDING MATERIAL WITH NON-PHENOLIC COLOR DEVELOPERS | SOLENIS TECHNOLOGIES CAYMAN, L.P. (KY) | 2021-03-04 | — | — | WO | disclosed |
| US-10343438-B2 | Heat-sensitive recording material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2019-07-09 | — | — | US | disclosed |
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-21 | — | — | US | disclosed |
| US-20170297355-A1 | Heat-Sensitive Recording Material | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2017-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | CSF1R, CSF3R, CD209 | TGM2 419/4885SMN1; SMN2 3016/4885TP53 3378/4885 |
| US-20170297355-A1 | Heat-Sensitive Recording Material | SCN1A, SCN3A, KCNN3 | TGM2 2430/4885SMN1; SMN2 219/4885TP53 4764/4885 |
| US-10343438-B2 | Heat-sensitive recording material | SCN1A, SCN3A, KCNN3 | TGM2 2430/4885SMN1; SMN2 219/4885TP53 4764/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.